Clinicogen is a GenoSensor, Inc. owned company started to focus on development and commercialization, either directly or through partners, of molecular assays for clinical applications. The company is specifically focused on cancer diagnostics for both screening and early detection as well as for monitoring the effectiveness of therapy.
Current efforts are focused on tests that are less invasive than current methodologies while providing similar or better sensitivity and specificity to current methodologies. Through this focus the company looks to improve adherence and compliance with cancer screening recommendations providing for earlier detection of disease when it is typically more treatable.
Clinicogen is leveraging its core competencies to build a strong product and technology portfolio of innovative and high quality molecular diagnostic products that can impact clinical decision making and patient outcomes. We are always interested in developing and fostering new partnership opportunities both in the area of development as well as commercialization.
Clinicogen is currently seeking licensees to commercialize the TheraLead CRC –
Early Colorectal Cancer Detection Test.
Clinicogen is a privately held company. The company has received the Angel Investment Program Certificate from the State of Arizona for qualified investors to generate tax credits of up to 35% of the investment amount. For more information about the program, visit Arizona Department of Commerce Small Business Incentives.